Have any questions?
+44 1234 567 890
Non-alcoholic fatty liver disease (NAFLD) - a new challenge for the healthcare system
Non-alcoholic fatty liver disease is primarily based on too little exercise combined with too much energy intake. Thus, it can be referred to as a lifestyle-related disease. It is estimated that every third person in Germany has fatty liver, which develops into fatty liver inflammation (NASH) in up to 5% of those affected. Progressive fatty liver inflammation can have far-reaching health complications such as cirrhosis or liver cancer. Medication has not been approved to date. The most important intervention for those affected is a permanent change in their lifestyle.
In addition, half of NAFLD patients have other diseases and disorders of the metabolism such as dyslipidaemia (50%) and type 2 diabetes mellitus (60%). In addition, patients are often affected by obesity (72%, BMI>30kg/m2) and hypertension (78%) (see Alsenbesy M et al. Z Gastroenterol 2019; 57: 1209-1217).
Examples of our project work
The innovation project funded by the GBA offers the first opportunity to develop lifestyle interventions to meet the needs of NASH patients.
NASH milieu study
How can you build a motivating, target group-specific communication that works sustainably with NASH patients?
Patient guideline EASL
Based on the clinical guideline of the EASL on NAFLD/NASH, a patient guideline was developed that explains fatty liver and its causes, consequences and (non) medical treatment options in a simple and patient-understandable way.